Ongoing Clinical Trials (Not Recruiting)

Access our list of ongoing clinical trials (Not Recruiting)

  • Revolution Medicines RMC-6291-001

    Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
    Study Link

    Atridia SHR-A1904-I-104
    An Open-label, Single-arm, Multi-center Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHRA1904 in Subjects with Advanced Solid Tumours Expressing Claudin 18.2
    Study Link

    Seagen SGNDV-005
    Phase 2 Basket Study of Disitamab Vedotin (ADC composed of the humanized anti-HER2 monoclonal antibody) in Adult Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors that Express HER2
    Study Link

  • USyd Enzamet

    Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
    Study Link

  • Daiichi Sankyo DS8201-A-U302

    A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
    Study Link

    Olema OP-1250-002

    A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer
    Study Link

    Hoffmann-La Roche WO41554

    A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
    Study Link

    BioNTech BNT327-02

    A Phase II, multi-site, randomized, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer
    Study Link

Click here to access a list of Current Trials